MRK - Merck & Co Inc
A global pharmaceutical leader whose Keytruda cancer immunotherapy is the best-selling drug in the world, supporting a robust oncology and vaccines pipeline.
Finlify Score
35.6 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$129.79
-0.44%
52W Range
$76.66 - $131.74
Market Cap
$317.4B
-0.4%Compared to previous day
2026 Q1 Revenue
$16.3B
-0.7%Changes from last reporting quarter
2026 Q1 EPS
$-1.72
Diluted shares
Analyst Rating
36 analysts in latest ratings feed
RSI
63.1
40-70 moderate
2Y Range Position
91%
-3.9% from high / +77.0% from low
Beta
0.21
Relative to market benchmark
MACD
0.17
MACD line 2.34 / signal line 2.17
Fundamental Trend
Growth 6.1Financial Health
Quality 27.9Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
AVOID35.6 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $16.3B-0.7% | $16.4B-5.1% | $17.3B+9.3% | $15.8B+1.8% |
| Gross Profit | - | - | - | - |
| Operating Income | - | - | - | - |
| Net Income | -$4.2B-243.1% | $3.0B-48.8% | $5.8B+30.7% | $4.4B-12.8% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jul 25, 2026
Finlify's signal for MRK on 2026-07-23 is AVOID, with a Finlify Score of 39.9 out of 100. This signal appears to be primarily driven by very low scores in Fundamental Trend and Financial Quality.
Technical
Technically, MRK exhibits strong Relative Strength at 69.7/100, suggesting favorable price momentum, while Accumulation / Volume is moderate at 53.0/100. The asset's RSI(14) of 61.2 indicates it may be approaching overbought conditions, and it is currently at its 52-week high with 0.0% distance. Recent performance includes an 8.2% return over 20 days and an 18.4% return over 60 days.
Fundamentals
The Fundamental Trend score is notably low at 6.1/100, which may indicate concerns regarding the company's recent fundamental performance. Financial Quality, at 27.9/100, also appears weak. Valuation metrics show a P/E of 17.7x, P/B of 5.0x, and P/S of 5.0x, while the asset offers a dividend yield of 2.61% and exhibits low volatility with a Beta of 0.2.
Macro Context
In the current macro environment, with CPI YoY at 3.7% and Core CPI at 2.8%, and a positive yield spread of 0.4%, the pharmaceutical sector, represented by MRK, may experience some stability given its defensive characteristics, though higher interest rates (10Y Treasury at 4.7%) could impact future growth funding.
Key Risks
- The very low Fundamental Trend score of 6.1/100 suggests potential underlying business weakness or deteriorating performance.
- A weak Financial Quality score of 27.9/100 may indicate concerns about the company's financial health or stability.
- The stock is currently at its 52-week high (0.0% distance), which could suggest limited immediate upside potential following recent strong performance.